Your browser doesn't support javascript.
loading
Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity
Wang, Guiying; Wu, Peng; Qiu, Yan; Dong, Xin; Wang, Yingbin; Chi, Yanjun; Zhang, Fengjuan; Li, Yinyu; Zhang, Jimin; Huang, Zhengli; Du, Xifeng; Du, Zhiqiang.
  • Wang, Guiying; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Wu, Peng; Shanghai Benemae Pharmaceutical Corporation. Shanghai. CN
  • Qiu, Yan; Shanghai Benemae Pharmaceutical Corporation. Shanghai. CN
  • Dong, Xin; Shanghai Benemae Pharmaceutical Corporation. Shanghai. CN
  • Wang, Yingbin; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Chi, Yanjun; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Zhang, Fengjuan; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Li, Yinyu; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Zhang, Jimin; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Huang, Zhengli; The First Affiliated Hospital of Datong University. Department of Endocrinology and Metabolism. Datong. CN
  • Du, Xifeng; Shanghai Benemae Pharmaceutical Corporation. Shanghai. CN
  • Du, Zhiqiang; Shanghai Benemae Pharmaceutical Corporation. Shanghai. CN
Arch. endocrinol. metab. (Online) ; 65(4): 421-427, July-Aug. 2021. tab, graf
Article in English | LILACS | ID: biblio-1339104
ABSTRACT
ABSTRACT

Objective:

To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers. Materials and

methods:

This study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m2 and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured.

Results:

After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021).

Conclusion:

Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 2 Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Shanghai Benemae Pharmaceutical Corporation/CN / The First Affiliated Hospital of Datong University/CN

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 2 Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2021 Type: Article Affiliation country: China Institution/Affiliation country: Shanghai Benemae Pharmaceutical Corporation/CN / The First Affiliated Hospital of Datong University/CN